Blood Cancer

Raritan, New Jersey, U.S., September 18, 2026 Johnson & Johnson has announced that the European Medicines Agency’s Committee for...

DUBLIN and BRIDGEWATER, N.J., August 31, 2026 Amarin Corporation plc highlighted new findings from multiple REDUCE-IT® analyses presented at...

BURLINGTON, Mass., August 31, 2026 PharmaEssentia announced that the U.S. Food and Drug Administration (FDA) has approved BESREMi® (ropeginterferon...

SYDNEY, Australia, August 26, 2026 HaemaLogiX Ltd has announced a key clinical development milestone with the first patient successfully...

WALTHAM, Mass., Aug. 5, 2026 Damora Therapeutics, Inc. has announced the initiation of the global Phase 1/1b CLARITY-101 clinical...

NEWTON, Mass., July 30, 2026 Karyopharm Therapeutics Inc. plans to submit a supplemental New Drug Application (sNDA) to the...

CAMBRIDGE, Mass., July 31, 2026 CREATE Medicines has announced a strategic research collaboration and exclusive worldwide licensing agreement with...

LEXINGTON, Mass., July 30, 2026 Curis, Inc. has reached an important clinical milestone by successfully dosing the first five...

COPENHAGEN, Denmark and NORTH CHICAGO, Ill., July 23, 2026 Genmab and AbbVie have issued a clarification regarding the Phase...

SYDNEY, Australia & INCHEON, South Korea, July 16, 2026 Organon and Samsung Bioepis have expanded their longstanding partnership through...